Primary Melanoma of the Vagina Treated by Imatinib: Case Report

Karima Oualla, Fatimazahra El’mrabet, Hind Elfatemi, Samia Arifi, Nawfel Mellas, Abdelaziz Banani, Siham Tizniti, Afaf Amarti, Omar Elmesbahi

Department of Medical Oncology, Hassan II University Hospital, Fez, Morocco.
Department of Pathology, Hassan II University Hospital, Fez, Morocco.

DOI: 10.4236/jct.2013.47134                

Abstract

Melanoma of the vagina is a rare lesion. It results from the malignant transformation of ectopic melanocytes occurring in post-menopause. The CKIT is expressed in 36% of cases in addition to melanoma markers. Prognosis is poor especially for inoperable and disseminated forms despite systemic therapy. Treatment with Imatinib is an option in cases of metastatic mucosal melanoma with CKIT mutation or amplification. We report the case of post-menopausal women, treated at Hassan II University Hospital, diagnosed with metastatic melanoma of the vagina, that didn’t respond to first line of chemotherapy, and received Imatinib as second line of treatment, with good clinical response and durable stability at radiological assessment.

Keywords

Mucosal Melanoma; Vagina; CKIT; Imatinib

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	G. Borazjoni, K. A. Prem, T. Ogakaki, et al., “Primary malignant Melanoma of the Vagina: A Clinicopathological Analysis of 10 Cases,” Gynecologic Oncology, Vol. 37, No. 2, 1990, pp. 264-267. doi:10.1016/0090-8258(90)90345-L
[2]	W. T. Creasman, J. L. Phillips and H. R. Menck, “The National Cancer Data Base Report on Cancer of the Vagina,” Cancer, Vol. 83, No. 5, 1998, pp. 1033-1040. doi:10.1002/(SICI)1097-0142(19980901)83:5<1033::AID-CNCR30>3.0.CO;2-6
[3]	B. Ragnarsson-Olding, H. Johansson, L. E. Rutqvist, et al., “Malignant Melanoma of the Vulva and Vagina. Trends in Incidence, Age Distribution, and Long-Term Survival among 245 Consecutive Cases in Sweden 19601984,” Cancer, Vol. 71, No. 5, 1993, pp. 1893-1897. doi:10.1002/1097-0142(19930301)71:5<1893::AID-CNCR2820710528>3.0.CO;2-7
[4]	H. Ikegaya, T. Iwasaki, I. Matsuda, et al., “Primary Amelanotic Malignant Melanoma of The Vagina—A Case Report,” Japan Journal of Cancer Clinics, Vol. 33, 1987, pp. 1515-1523 (in Japanese).
[5]	D. Gupta, A. Malpica, M. T. Deavers, et al., “Vaginal Melanoma: A Clinicopathologic and Immunohistochemical Study of 26 Cases,” American Journal of Surgical Pathology, Vol. 26, No. 11, 2002, pp. 1450-1457. doi:10.1097/00000478-200211000-00007
[6]	B. Piura, “Management of Primary Melanoma of the Female Urogenital Tract,” Lancet Oncology, Vol. 9, No. 10, 2008, pp. 973-981. doi:10.1016/S1470-2045(08)70254-7
[7]	V. E. Sugiyamaa, J. K. Chana and D. S. Kappb, “Management of Melanomas of the Female Genital Tract,” Current Opinion in Oncology, Vol. 20, No. 5, 2008, pp. 565-569. doi:10.1097/CCO.0b013e32830b0dda
[8]	E. Petru, F. Nagele, K. Czerwenka, et al., “Primary Malignant Melanoma of the Vagina: A Long Term Remission Following Radiation Therapy,” Gynecologic Oncology, Vol. 70, No. 1, 1998, pp. 23-26. doi:10.1006/gyno.1998.4982
[9]	M. A. Weinstock, “Malignant Melanoma of the Vulva and Vagina in the United States: Patterns of Incidence and Population-Based Estimates of Survival,” American Journal of Obstetrics & Gynecology, Vol. 171, No. 5, 1994, pp. 1225-1230. doi:10.1016/0002-9378(94)90137-6
[10]	H. Davies, G. R. Bignell, C. Cox, et al., “Mutations of the BRAF Gene in Human Cancer,” Nature, Vol. 417, No. 6892, 2002, pp. 949-954. doi:10.1038/nature00766
[11]	J. A. Curtin, K. Busam, D. Pinkel and B. C. Bastian, “Somatic Activation of KIT in Distinct Subtypes of Melanoma,” Journal of Clinical Oncology, Vol. 24, No. 26, 2006, pp. 4340-4346. doi:10.1200/JCO.2006.06.2984
[12]	C. Beadling, E. Jacobson-Dunlop, F. S. Hodi, et al., “KIT Gene Mutations and Copy Number in Melanoma Subtypes,” Clinical Cancer Research, Vol. 14, No. 21, 2008, pp. 6821-6828. doi:10.1158/1078-0432.CCR-08-0575
[13]	L. Hou, J. J. Panthier and H. Arnheiter, “Signaling and Transcriptional Regulation in the Neural Crest-Derived Melanocyte Lineage: Interactions between KIT and MITF,” Development, Vol. 127, No. 24, 2000, pp. 5379-5389.
[14]	V. Alexeev and K. Yoon, “Distinctive Role of the cKit Receptor Tyrosine Kinase Signaling in Mammalian Melanocytes,” Journal of Investigative Dermatology, Vol. 126, No. 5, 2006, pp. 1102-1110. doi:10.1038/sj.jid.5700125
[15]	K. Wyman, M. B. Atkins, V. Prieto, et al., “Multicenter Phase II Trial of High-Dose Imatinib Mesylate in Metastatic Melanoma: Significant Toxicity with No Clinical Efficacy,” Cancer, Vol. 106, No. 9, 2006, pp. 2005-2011. doi:10.1002/cncr.21834
[16]	K. B. Kim, O. Eton, D. W. Davis, et al., “Phase II Trial of Imatinib Mesylate in Patients with Metastatic Melanoma,” British Journal of Cancer, Vol. 99, No. 5, 2008, pp. 734-740. doi:10.1038/sj.bjc.6604482
[17]	G. D. Demetri, M. von Mehren, C. D. Blanke, et al., “Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors,” New England Journal of Medicine, Vol. 347, No. 7, 2002, pp. 472-480. doi:10.1056/NEJMoa020461
[18]	C. R. Antonescu, K. J. Busam, T. D. Francone, et al., “L576P KIT Mutation in Anal Melanomas Correlates with KIT Protein Expression and Is Sensitive to Specific Kinase Inhibition,” International Journal of Cancer, Vol. 121, No. 2, 2007, pp. 257-264. doi:10.1002/ijc.22681
[19]	X. Jiang, J. Zhou, N. K. Yuen, et al., “Imatinib Targeting of KIT-Mutant Oncoprotein in Melanoma,” Clinical Cancer Research, Vol. 14, No. 23, 2008, pp. 7726-7732. doi:10.1158/1078-0432.CCR-08-1144
[20]	F. S. Hodi, P. Friedlander, C. L. Corless, et al., “Major response to Imatinib Mesylate in KIT-Mutated Melanoma,” Journal of Clinical Oncology, Vol. 26, No. 12, 2008, pp. 2046-2051. doi:10.1200/JCO.2007.14.0707
[21]	J. Lutzky, J. Bauer and B. C. Bastian, “Dose-Dependent, Complete Response to Imatinib of a Metastatic Mucosal Melanoma with a K642E KIT Mutation,” Pigment Cell & Melanoma Research, Vol. 21, No. 4, 2008, pp. 492-493. doi:10.1111/j.1755-148X.2008.00475.x